Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Alzheimer's Disease

Free Subscription Articles published in N Engl J Med Retrieve available abstracts of 34 articles: HTML format

Single Articles

June 2024
1. CHIN NA, Erickson CM
   Alzheimer's Disease, Biomarkers, and mAbs - What Does Primary Care Need?
   N Engl J Med. 2024;390:2229-2231.
   PubMed    
   
   
   
2. STEFANSSON H, Walters GB, Sveinbjornsson G, Tragante V, et al
   Homozygosity for R47H in TREM2 and the Risk of Alzheimer's Disease.
   N Engl J Med. 2024;390:2217-2219.
   PubMed    
   
   
   
3. HARDY J
   Protection against Alzheimer's Disease with APOE Christchurch Variant - How?
   N Engl J Med. 2024;390:2212-2213.
   PubMed    
   
   
   
4. QUIROZ YT, Aguillon D, Aguirre-Acevedo DC, Vasquez D, et al
   APOE3 Christchurch Heterozygosity and Autosomal Dominant Alzheimer's Disease.
   N Engl J Med. 2024;390:2156-2164.
   PubMed     Abstract available
   
   
   March 2024
5. CHIN NA, Dinsmore D, Gonzales T, Groves B, et al
   Alzheimer's Disease - Managing Stages of Dementia.
   N Engl J Med. 2024;390:e29.
   PubMed    
   
   
   
6. CHIN NA, Dinsmore D, Gonzales T, Groves B, et al
   Alzheimer's Disease - Anti-Amyloid Medications, Early Detection, and Screening.
   N Engl J Med. 2024;390:e22.
   PubMed    
   
   
   February 2024
7. BATEMAN RJ, Smith J, Doody RS
   Gantenerumab in Early Alzheimer's Disease. Reply.
   N Engl J Med. 2024;390:867.
   PubMed    
   
   
   
8. WANG Z, Zhao B, Jia J
   Gantenerumab in Early Alzheimer's Disease.
   N Engl J Med. 2024;390:866.
   PubMed    
   
   
   
9. MAYEUX R
   Alzheimer's Disease Biomarkers - Timing Is Everything.
   N Engl J Med. 2024;390:761-763.
   PubMed    
   
   
   
10. JIA J, Ning Y, Chen M, Wang S, et al
    Biomarker Changes during 20 Years Preceding Alzheimer's Disease.
    N Engl J Med. 2024;390:712-722.
    PubMed     Abstract available
    
    
    January 2024
11. REZAI AR, D'Haese PF, Finomore V, Carpenter J, et al
    Ultrasound Blood-Brain Barrier Opening and Aducanumab in Alzheimer's Disease.
    N Engl J Med. 2024;390:55-62.
    PubMed     Abstract available
    
    
    November 2023
12. 
    Alzheimer's Update, Part 2: ITT Episode 21.
    N Engl J Med. 2023;389:e43.
    PubMed    
    
    
    
13. SCHNEIDER LS
    What the Gantenerumab Trials Teach Us about Alzheimer's Treatment.
    N Engl J Med. 2023;389:1918-1920.
    PubMed    
    
    
    
14. BATEMAN RJ, Smith J, Donohue MC, Delmar P, et al
    Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease.
    N Engl J Med. 2023;389:1862-1876.
    PubMed     Abstract available
    
    
    
15. 
    Alzheimer's Update, Part 1: ITT Episode 20.
    N Engl J Med. 2023;389:e33.
    PubMed    
    
    
    July 2023
16. SPERLING RA, Donohue MC, Raman R, Rafii MS, et al
    Trial of Solanezumab in Preclinical Alzheimer's Disease.
    N Engl J Med. 2023 Jul 17. doi: 10.1056/NEJMoa2305032.
    PubMed     Abstract available
    
    
    April 2023
17. VAN DYCK CH, Sabbagh M, Cohen S
    Lecanemab in Early Alzheimer's Disease. Reply.
    N Engl J Med. 2023;388:1631-1632.
    PubMed    
    
    
    
18. BRENMAN JE
    Lecanemab in Early Alzheimer's Disease.
    N Engl J Med. 2023;388:1631.
    PubMed    
    
    
    
19. POMARA N, Imbimbo BP
    Lecanemab in Early Alzheimer's Disease.
    N Engl J Med. 2023;388:1630-1631.
    PubMed    
    
    
    
20. VALENZUELA MJ, Pascual-Leone A
    Lecanemab in Early Alzheimer's Disease.
    N Engl J Med. 2023;388:1630.
    PubMed    
    
    
    
21. ZENG BS, Tseng PT, Liang CS
    Lecanemab in Early Alzheimer's Disease.
    N Engl J Med. 2023;388:1630.
    PubMed    
    
    
    January 2023
22. GANDY S, Ehrlich ME
    Moving the Needle on Alzheimer's Disease with an Anti-Oligomer Antibody.
    N Engl J Med. 2023;388:80-81.
    PubMed    
    
    
    
23. SABBAGH M, van Dyck CH
    Response to: Multiple Cerebral Hemorrhages in a Patient Receiving Lecanemab and Treated with t-PA for Stroke.
    N Engl J Med. 2023 Jan 4:10.1056/NEJMc2215907#sa1. doi: 10.1056/NEJMc2215907.
    PubMed    
    
    
    November 2022
24. VAN DYCK CH, Swanson CJ, Aisen P, Bateman RJ, et al
    Lecanemab in Early Alzheimer's Disease.
    N Engl J Med. 2022 Nov 29. doi: 10.1056/NEJMoa2212948.
    PubMed     Abstract available
    
    
    November 2021
25. SACHS RE, Bagley N
    Medicare Coverage of Aducanumab - Implications for State Budgets.
    N Engl J Med. 2021;385:2019-2021.
    PubMed    
    
    
    
26. ROBINSON JC
    Why Is Aducanumab Priced at $56,000 per Patient? Lessons for Drug-Pricing Reform.
    N Engl J Med. 2021;385:2017-2019.
    PubMed    
    
    
    August 2021
27. ALEXANDER GC, Knopman DS, Emerson SS, Ovbiagele B, et al
    Revisiting FDA Approval of Aducanumab.
    N Engl J Med. 2021;385:769-771.
    PubMed    
    
    
    
28. MINTUN MA, Wessels AM, Sims JR
    Donanemab in Early Alzheimer's Disease. Reply.
    N Engl J Med. 2021;385:667.
    PubMed    
    
    
    
29. ESPAY AJ
    Donanemab in Early Alzheimer's Disease.
    N Engl J Med. 2021;385:666-667.
    PubMed    
    
    
    July 2021
30. RABINOVICI GD
    Controversy and Progress in Alzheimer's Disease - FDA Approval of Aducanumab.
    N Engl J Med. 2021 Jul 28. doi: 10.1056/NEJMp2111320.
    PubMed    
    
    
    
31. DUNN B, Stein P, Temple R, Cavazzoni P, et al
    An Appropriate Use of Accelerated Approval - Aducanumab for Alzheimer's Disease.
    N Engl J Med. 2021 Jul 28. doi: 10.1056/NEJMc2111960.
    PubMed    
    
    
    May 2021
32. LEVEY AI
    Progress with Treatments for Alzheimer's Disease.
    N Engl J Med. 2021;384:1762-1763.
    PubMed    
    
    
    March 2021
33. MINTUN MA, Lo AC, Duggan Evans C, Wessels AM, et al
    Donanemab in Early Alzheimer's Disease.
    N Engl J Med. 2021 Mar 13. doi: 10.1056/NEJMoa2100708.
    PubMed     Abstract available
    
    
    October 2020
34. FRIED LP, Rowe JW
    Health in Aging - Past, Present, and Future.
    N Engl J Med. 2020;383:1293-1296.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Alzheimer's Disease is free of charge.